Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

292 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Successful treatment of sino-pulmonary infection & skull base osteomyelitis caused by New Delhi metallo-β-lactamase-producing Pseudomonas aeruginosa in a renal transplant recipient by using an investigational antibiotic cefepime/zidebactam (WCK 5222).
Soman R, Sirsat R, Sunavala A, Punatar N, Mehta J, Rodrigues C, Veeraraghavan B. Soman R, et al. Among authors: veeraraghavan b. Eur J Clin Microbiol Infect Dis. 2024 Feb 28. doi: 10.1007/s10096-024-04791-1. Online ahead of print. Eur J Clin Microbiol Infect Dis. 2024. PMID: 38416290
Antimicrobial susceptibility profiles of gram-negative bacteria causing infections collected across India during 2014-2016: Study for monitoring antimicrobial resistance trend report.
Veeraraghavan B, Jesudason MR, Prakasah JAJ, Anandan S, Sahni RD, Pragasam AK, Bakthavatchalam YD, Selvakumar RJ, Dhole TN, Rodrigues C, Roy I, Joshi S, Chaudhuri BN, Chitnis DS. Veeraraghavan B, et al. Indian J Med Microbiol. 2018 Jan-Mar;36(1):32-36. doi: 10.4103/ijmm.IJMM_17_415. Indian J Med Microbiol. 2018. PMID: 29735823 Free article.
Newer β-Lactam/β-Lactamase inhibitor for multidrug-resistant gram-negative infections: Challenges, implications and surveillance strategy for India.
Veeraraghavan B, Pragasam AK, Bakthavatchalam YD, Anandan S, Ramasubramanian V, Swaminathan S, Gopalakrishnan R, Soman R, Abraham OC, Ohri VC, Walia K. Veeraraghavan B, et al. Indian J Med Microbiol. 2018 Jul-Sep;36(3):334-343. doi: 10.4103/ijmm.IJMM_18_326. Indian J Med Microbiol. 2018. PMID: 30429384 Free article. Review.
Activity of cefepime/zidebactam against MDR Escherichia coli isolates harbouring a novel mechanism of resistance based on four-amino-acid inserts in PBP3.
Bhagwat SS, Hariharan P, Joshi PR, Palwe SR, Shrivastava R, Patel MV, Devanga Ragupathi NK, Bakthavatchalam YD, Ramesh MS, Soman R, Veeraraghavan B. Bhagwat SS, et al. Among authors: veeraraghavan b. J Antimicrob Chemother. 2020 Dec 1;75(12):3563-3567. doi: 10.1093/jac/dkaa353. J Antimicrob Chemother. 2020. PMID: 32772098
Is it time to move away from polymyxins?: evidence and alternatives.
Soman R, Bakthavatchalam YD, Nadarajan A, Dwarakanathan HT, Venkatasubramanian R, Veeraraghavan B. Soman R, et al. Among authors: veeraraghavan b. Eur J Clin Microbiol Infect Dis. 2021 Mar;40(3):461-475. doi: 10.1007/s10096-020-04053-w. Epub 2020 Oct 2. Eur J Clin Microbiol Infect Dis. 2021. PMID: 33009595 Review.
292 results